NYSE:PFE - Pfizer Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$42.4250 -0.30 (-0.70 %)
(As of 01/16/2019 11:25 AM ET)
Previous Close$42.73
Today's Range$42.4150 - $42.7921
52-Week Range$33.20 - $46.47
Volume8.45 million shs
Average Volume23.97 million shs
Market Capitalization$252.22 billion
P/E Ratio16.01
Dividend Yield3.21%
Beta0.87
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brands. This segment also engages in the research and development, as well as contract manufacturing activities. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; Immunicum AB (publ); Immutep Limited; BioNTech AG; Neofluidics, LLC; Kite Pharma, Inc.; Leap Therapeutics, Inc.; Nektar Therapeutics; Zenith Epigenetics Ltd., and Kineta Immuno-Oncology, LLC, as well as development agreement with Antares Pharma, Inc. It also has a collaboration agreement with Aileron Therapeutics, Inc. The company was founded in 1849 and is headquartered in New York, New York.

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP71708110
Phone212-733-2323

Debt

Current Ratio1.43
Quick Ratio1.15

Price-To-Earnings

Sales & Book Value

Annual Sales$52.55 billion
Price / Sales4.81
Cash Flow$3.7544 per share
Price / Cash Flow11.30
Book Value$12.02 per share
Price / Book3.53

Profitability

Net Income$21.31 billion
Net Margins44.63%
Return on Assets10.72%

Miscellaneous

Employees90,200
Outstanding Shares5,952,870,000
Market Cap$252.22 billion
OptionableOptionable

Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer announced a quarterly dividend on Friday, December 14th. Stockholders of record on Friday, February 1st will be paid a dividend of $0.36 per share on Friday, March 1st. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.37%. The ex-dividend date of this dividend is Thursday, January 31st. This is a boost from Pfizer's previous quarterly dividend of $0.34. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer announced that its board has initiated a share repurchase program on Friday, December 14th 2018, which authorizes the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to buy up to 3.8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's management believes its stock is undervalued.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) announced its quarterly earnings data on Tuesday, October, 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.03. The biopharmaceutical company had revenue of $13.30 billion for the quarter, compared to the consensus estimate of $13.53 billion. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The business's revenue was up 1.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.67 EPS. View Pfizer's Earnings History.

When is Pfizer's next earnings date?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, January 29th 2019. View Earnings Estimates for Pfizer.

How can I listen to Pfizer's earnings call?

Pfizer will be holding an earnings conference call on Tuesday, January 29th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8553588231.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY18 earnings guidance on Tuesday, October, 30th. The company provided earnings per share guidance of $2.98-3.02 for the period, compared to the Thomson Reuters consensus estimate of $2.99. The company issued revenue guidance of $53-53.7 billion, compared to the consensus revenue estimate of $54.16 billion.

What price target have analysts set for PFE?

22 analysts have issued 12-month target prices for Pfizer's shares. Their predictions range from $37.00 to $54.00. On average, they expect Pfizer's share price to reach $43.80 in the next twelve months. This suggests a possible upside of 2.5% from the stock's current price. View Analyst Price Targets for Pfizer.

What is the consensus analysts' recommendation for Pfizer?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 2 sell ratings, 13 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

What are Wall Street analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:
  • 1. Cantor Fitzgerald analysts commented, "We reiterate our OW and think respectable earnings growth, driven by Innovative Medicines, pipeline advancements, and return of capital to PFE’s shareholders — above the industry average — are all underappreciated. Therefore, we believe multiple expansion and upward earnings revisions should drive PFE shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $53." (12/11/2018)
  • 2. According to Zacks Investment Research, "Pfizer is facing top-line headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition. Nonetheless, we believe that new products like Ibrance, contribution from acquisitions, cost-cutting efforts, a lower tax rate and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals through 2022, including around 15 products that have blockbuster potential. Pfizer’s growing immuno-oncology portfolio has strong potential.  Bavencio is being considered a key long-term growth driver for Pfizer. In oncology, Pfizer has three potential medicines under FDA’s priority review. The stock has outperformed the industry this year so far. Estimates have remained stable ahead of its Q3 earnings release and Pfizer has a positive record of earnings surprises in recent quarters." (10/16/2018)

Has Pfizer been receiving favorable news coverage?

Press coverage about PFE stock has been trending positive this week, according to InfoTrie. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pfizer earned a news sentiment score of 2.8 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an effect on the company's share price in the immediate future.

Are investors shorting Pfizer?

Pfizer saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 49,740,738 shares, a decrease of 16.6% from the December 14th total of 59,611,012 shares. Based on an average trading volume of 30,670,201 shares, the days-to-cover ratio is presently 1.6 days. Approximately 0.9% of the company's shares are sold short. View Pfizer's Current Options Chain.

Who are some of Pfizer's key competitors?

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:
  • Mr. Ian C. Read, Exec. Chairman (Age 65)
  • Mr. Frank A. D'Amelio, CFO & EVP of Global Supply, Bus. Operations and Manufacturing Operations of Pfizer Global Supply (Age 61)
  • Dr. Mikael Dolsten, Chief Medical Officer and Global Pres of Worldwide R&D and Medical (Age 60)
  • Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 54)
  • Ms. Loretta V. Cangialosi, Sr. VP, Controller & Principal Accounting Officer

Who are Pfizer's major shareholders?

Pfizer's stock is owned by a number of of institutional and retail investors. Top institutional investors include Hexavest Inc. (0.08%), Gateway Investment Advisers LLC (0.05%), Retirement Systems of Alabama (0.05%), Confluence Investment Management LLC (0.04%), KAMES CAPITAL plc (0.03%) and Cornerstone Investment Partners LLC (0.03%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

Which major investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including Gulf International Bank UK Ltd, Hexavest Inc., Retirement Systems of Alabama, Factory Mutual Insurance Co., Sit Investment Associates Inc., DNB Asset Management AS, Virtu Financial LLC and Visionary Asset Management Inc.. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

Which major investors are buying Pfizer stock?

PFE stock was bought by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, Centre Asset Management LLC, Town & Country Bank & Trust CO dba First Bankers Trust CO, Atalanta Sosnoff Capital LLC, Grassi Investment Management, Steward Partners Investment Advisory LLC, Gateway Investment Advisers LLC and YHB Investment Advisors Inc.. View Insider Buying and Selling for Pfizer.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $42.74.

How big of a company is Pfizer?

Pfizer has a market capitalization of $252.22 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

What is Pfizer's official website?

The official website for Pfizer is http://www.pfizer.com.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.


MarketBeat Community Rating for Pfizer (NYSE PFE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,238 (Vote Outperform)
Underperform Votes:  715 (Vote Underperform)
Total Votes:  1,953
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Featured Article: How is inflation measured?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel